Are there Long Term Health Risks associated with the Spike Protein?

Researchers focused on spike protein effects and entry mechanisms • 0:00

Collaboration with global groups to combat COVID-19 since early pandemic • 1:50

Focus on understanding damages and mitigation strategies • 3:11

Research group leader from Pakistan with expertise in infectious diseases • 3:53

Importance of spike protein in viral entry and vaccine mechanisms • 4:36

Investigation into blocking viral entry and replication processes • 5:40

Study of mRNA vaccine effects on spike protein production and excretion • 6:14

Increased cancer cases post-pandemic, attributed to various health issues like thrombosis and organ damage • 6:31

Neurological damage, brain inflammation, and organ damage observed in individuals affected by spike protein and vaccine injuries • 7:29

Hypersensitivity, autoimmune reactions, and immunodeficiency noted as ongoing issues post-exposure to spike protein and SARS-CoV-2 • 8:06

German Health Minister confirms vaccine injuries and calls for research funding from vaccine companies • 9:28

Long COVID symptoms persisting in some patients globally, with variations based on genetic makeup and geographic location • 11:09

Spike protein in mRNA vaccines modified with two Proline substitutions to prevent binding to ACE2 receptor • 15:39

Question raised on the efficacy of mRNA vaccines in producing functional spike proteins • 16:44

Modifications hinder the configurational change necessary for virus entry into the cell • 16:44

Vaccines produce spike protein, not virus, to trigger immune response • 17:05

Proline substitutions prevent spike protein binding to receptors • 18:24

Variants evolve to bind to different receptors, causing varied symptoms • 20:10

New spike protein variants may impact blood-brain barrier and neurotropism • 21:09

Inhibitors may be needed to block new variant spike protein interactions • 21:48

Boosters may be necessary to counteract evolving spike protein variants • 22:08

Developers faced unknown unknowns during vaccine development due to the novel virus • 22:29

Lack of proactive education about the vaccine and virus in the initial months of the pandemic • 23:28

Surprise at the virus’s use of multiple entry mechanisms and substitutions in the spike protein • 24:29

Speculation on the possibility of the virus being man-made due to its sophisticated features • 26:15

Viruses evolving and changing entry mechanisms pose challenges for drug effectiveness • 27:34

Clinical trials focusing on bacterial infections and viral reproduction inhibition • 27:53

Concerns about mutations in the main protease affecting drug efficacy • 28:32

Comparison of SARS-CoV-2 with other highly dangerous viruses like Epstein-Barr • 29:07

Lack of continued research on previous viruses like SARS-CoV-1 and potential risks • 29:49

Importance of exploring mucosal vaccines for better immunity and prevention strategies • 30:29

Recognition of the need for diversified funding in drug research beyond vaccines • 30:51

Discussion on the limitations of current vaccine strategies in controlling the pandemic • 31:37

Advocacy for exploring alternative solutions like mucosal vaccines for better prevention • 31:59

Various immune cells are affected by the spike protein, leading to functional deficiencies • 32:39

Long Covid patients and those with excess spike protein production show imbalances in CD4, CD5, CD3, and CD8 cells • 35:39

Some individuals may have normal T and B cell counts but experience functional lymphocytopenia • 36:19

Dual factor of quantitative lymphocytopenia and qualitative immune deficiency • 37:52

Qualitative immune deficiency can only be diagnosed through functional testing of T cells • 38:16

Suggested testing of lymphocytes in a Petri dish to assess qualitative damage • 38:47

Macrophages also qualitatively and quantitatively damaged, impacting immune response • 39:40

Bacterial infections not combated well due to immune deficiencies, leading to prolonged infections • 39:58

Rise of fungal infections due to compromised immunity and dysbiosis in the gut biome • 40:17

Direct infection of bacteria by virus affecting gut biome and leading to overgrowth of pathogenic bacteria • 41:21

Infection impacting mucosal immunity and ability to prevent virus from entering bloodstream • 42:47

Spike protein affects mucosal immunity in the respiratory system, reducing its efficiency • 43:08

Spike protein suppresses type 1 interferon, making individuals more susceptible to infections • 43:30

Damage to endothelium by Spike protein leads to thrombosis, not just clotting • 46:30

Endothelial damage caused by Spike protein increases the risk of thrombosis • 47:27

Spike protein is detrimental to endothelium and triggers a cascade of thrombosis • 47:50

The mechanism of clot formation in thrombosis is similar to normal clotting but occurs without external damage • 48:11

Endothelial cells damaged by Spike protein increase the likelihood of thrombus formation • 48:29

Endothelium damage leads to thrombus formation and organ collapse • 48:48

Spike protein from vaccines can damage endothelium and cause thrombosis • 49:05

Similarities in health outcomes between COVID and vaccine-related injuries • 49:24

Not everyone is equally at risk for adverse effects, but specific percentages are unknown • 50:21

Lack of funding for studies on predisposition to vaccine injuries • 50:42

Diagnostic tools for post-viral conditions like microthrombi are lacking • 51:22

Endothelial debris found in blood samples of all patients, indicating widespread damage • 52:00

Variation in health impact observed in different populations based on factors like immunity and chronic diseases • 53:06

Developed countries facing more health issues compared to less developed regions • 53:29

Population in Africa, India, and Papua New Guinea may have healthier biome due to biodiversity • 53:48

Underlying inflammation caused by industrial food and lifestyle contributes to chronic diseases • 54:08

Combination of inflammation and spike protein can lead to severe health complications • 54:27

Neonates may not be significantly affected by spike protein due to poor immunity • 54:45

Healthy individuals with balanced diets can also be affected by viral load and comorbidities • 55:06

Micro thrombi with rubber-like consistency can be difficult to disintegrate • 56:27

Treatment with certain products can improve micro thrombi and dampen inflammation • 57:05

Neutrophil elastase fibers result from the combination of spike protein and neutrophils • 58:50

Research on Spike proteins causing insoluble fibers similar to Alzheimer’s amyloid • 59:15

Hypothesis on how Spike proteins trigger clot formation in inflammatory conditions • 59:58

Exploration of enzymes to break down fibrils and remove Spike proteins from cells • 1:01:18

Efforts to develop a common protocol to address health issues caused by Spike proteins • 1:03:25

Need for more specialized and individualized medicine for complex health conditions • 1:04:02

Importance of distinguishing the root cause to effectively address health problems • 1:04:19

Micro thrombi are effects, not causes of health issues • 1:04:38

Identifying the provocating agent like Sars-Cov-2 is crucial for treatment • 1:04:55

Progress has been made in understanding and treating the health risks • 1:05:16

Appreciation for sharing research insights and looking forward to future findings • 1:05:35

Acknowledgment and gratitude for the audience and researchers • 1:07:29